Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miconazole + mometasone + nadifloxacin
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Afdol-MN is a topical combination cream developed by Anglo-French Drugs & Industries for the treatment of mixed bacterial, fungal, and inflammatory skin conditions. It contains three active ingredients: nadifloxacin (a broad-spectrum fluoroquinolone antibiotic), miconazole (an imidazole antifungal), and mometasone (a mid-potent corticosteroid). Nadifloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby disrupting DNA replication. Miconazole acts as an antifungal by inhibiting lanosterol 14-alpha demethylase, which prevents ergosterol synthesis and disrupts fungal cell membrane integrity. Mometasone binds to the glucocorticoid receptor to reduce the production of inflammatory mediators, relieving itching, redness, and swelling. This triple-action formulation is indicated for various dermatological conditions, including tinea infections, eczema, dermatitis, and secondary bacterial or fungal skin infections.
- Brand names
- Afdol-MNAfdol-MN Cream
- Other names
- miconazole + mometasone + nadifloxacin creammiconazole nitrate + mometasone furoate + nadifloxacinmiconazole nitrate + mometasone furoate + nadifloxacin cream
02
Targets
FOS (Activator Protein 1)DNA gyraseTopo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)NF-κB
Beyond the preview
Go deeper on miconazole + mometasone + nadifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miconazole + mometasone + nadifloxacin.